Skip to main content

Table 5 Comparison of total pill burden and pill burden from PBs between users and non-users of oral/IV calcimimetics and VDRAs. PBs were further analyzed separately for Ca-based PB (Ca carbonate) and non-Ca-based PBs (PBs other than Ca carbonate)

From: Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients

 

Prescription

Patients

Total pill burden

 

Pill burden from all PBs

 

Pill burden from Ca-based PB

 

Pill burden from non-Ca-based PBs

 

yes/no

n (%)

pills/day/patient

(P)

pills/day/patient

(P)

pills/day/patient

(P)

pills/day/patient

(P)

Oral calcimimetics

Non-user

378 (70.9)

13.9 ± 6.7

< 0.001

5.77 ± 4.13

< 0.001

4.03 ± 1.91

< 0.001

4.49 ± 2.87

0.020

 (evocalcet)

User

155 (29.1)

17.8 ± 8.7

7.80 ± 5.66

5.05 ± 2.06

5.75 ± 4.29

IV caclimimetics

Non-user

462 (86.7)

14.8 ± 7.6

0.005

6.26 ± 4.74

0.040

4.29 ± 2.03

0.074

4.87 ± 3.54

0.209

 (etelcalcetide HCl)

User

71 (13.3)

16.9 ± 7.0

7.43 ± 4.92

4.79 ± 1.84

5.31 ± 3.31

Oral VDRAs

Non-user

392 (73.5)

15.4 ± 8.0

0.208

6.81 ± 4.96

0.001

4.57 ± 1.98

< 0.001

5.00 ± 3.69

0.701

 (calcitriol, alfacalcidol)

User

141 (26.5)

14.1 ± 6.3

5.36 ± 4.08

3.68 ± 1.98

4.78 ± 2.82

IV VDRAs

Non-user

245 (46.0)

14.6 ± 7.2

0.360

6.12 ± 4.70

0.088

4.16 ± 2.11

0.054

5.06 ± 3.31

0.476

 (calcitriol, maxacalcitol)

User

288 (54.0)

15.4 ± 7.9

6.68 ± 4.84

4.52 ± 1.93

4.88 ± 3.62